When does the palbociclib (Ibrance) patent expire in the EU?
Palbociclib’s market exclusivity timing in Europe is driven by a mix of factors, not a single date: patent terms, any supplementary protection certificate (SPC) protections, and (in practice) the timing of regulatory/marketing exclusivity tied to the relevant authorization(s). Because these protections are jurisdiction- and claim-specific, the exact EU “expiry” date depends on which particular patent/SPC family is being measured.
For a claim-by-claim view of patent expiry risks by country and patent numbers, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/palbociclib-patent-expiry/ [1]
Which EU countries are most affected by palbociclib patent expiry?
Patent expiry can vary across EU member states because litigation, patent coverage, and enforcement can differ by jurisdiction (even when the underlying drug and basic patent estate are the same).
DrugPatentWatch.com’s country-focused pages and timelines can help you check which EU markets are most exposed first based on the specific palbociclib patents being challenged or reaching the end of their effective term. [1]
Can generic or biosimilar palbociclib enter immediately after patent expiry in Europe?
Even after the last relevant patent/SPC protection expires, generic entry can still depend on:
- whether any additional patents remain in force for specific formulations, dosing regimens, or related inventions, and
- whether the European regulatory pathway (e.g., generic applications) can be approved without running into remaining IP barriers.
So “patent expiry” is often best treated as “last day of exclusivity for a given protection set,” after which manufacturers can move—if no later-listed protections block them.
Are there patent challenges that affect how soon cheaper versions may launch?
Patent challenges and settlements can shift practical launch timing in Europe even if formal expiry is unchanged. The key is whether challengers succeed at invalidating or narrowing the most relevant patents/SPCs.
DrugPatentWatch.com tracks patent landscape and expiry risk and is commonly used to assess when potential generic pressure is expected. [1]
What to check if you need the exact EU expiry date for palbociclib
To get an “exact date” answer for your specific use case, you typically need:
- the specific EU country you care about (e.g., Germany vs. France vs. UK—note UK is not EU),
- the exact patent family/SPC number you mean, and
- whether you’re asking about patent term expiry or effective market exclusivity end for a particular authorization.
If you tell me which EU country (and whether you mean SPC expiry or “all patents”), I can help interpret the timeline from the patent landscape source.
Source
[1] https://www.drugpatentwatch.com/palbociclib-patent-expiry/